Search Results
Profectus begins PhI HIV vax trial with 'prime-boost' delivery
Profectus BioSciences, a vaccine developer with a focus on DNA-based applications, began a Phase I clinical trial of its HIV vaccine, which makes use of the TriGrid electroporation delivery system the company licensed from Ichor Medical Systems. Using a "prime-boost" vaccination regimen, ...
Veritas wins European patent for RNA delivery method
allowed in the U.S. already, and is in the process of filing other applications to expand its RNA-drug ...
Actavis rolls out generic Lidoderm patch; Daiichi shares plunge on new FDA import restrictions;
Visterra antibody shows promise in preclinical study as universal flu vaccine. Item > NIH partners with Eli Lilly, others on rare diseases. Article > Experimental vaccine clears monkeys of HIV-like ...
Troubled Dendreon gets EC OK for Provenge; Acacia launches pivotal studies;
> Visterra antibody shows promise in preclinical study as universal flu vaccine. Item > NIH partners with Eli Lilly, others on rare diseases. Article > Experimental vaccine clears monkeys ...
Biotechs keep the cash pumping (for now) with more IPOs and ATMs
PhII Langer's Bind files $80M IPO as new biotech offerings go gangbusters Five Prime Therapeutics ...
Boston Scientific scores solid results for TAVR device; JenaValve nails down expanded CE mark;
promise in preclinical study as universal flu vaccine. Item > NIH partners with Eli Lilly, others on rare diseases. Article > Experimental vaccine clears monkeys of HIV-like virus. More > Genia ...
Boston Scientific, OrbusNeich call cease-fire in stent fight
including the top-selling Promus Element and newly released Promus Premier. OrbusNeich first filed suit ...
UPDATED: Strides gets FDA warning for plant Mylan is buying
drug unit it is selling to Mylan ($MYL) for $1.6 billion. In a filing with the Indian stock exchange, ...
Veeva, provider of sales software to Merck, seeks up to $150M in IPO
in April that Veeva was likely to attempt an IPO this year.- here's the S-1 filing- and an article ...
Unvaccinated clusters bear brunt of bad year for measles in U.S.
the 10% of people who decline the measles vaccine are distributed. Most of the country is above the 90% immunization target, but in certain communities the vaccination rate is much lower. When a virus is introduced ...
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
